Kwinten Sliepen

This paper develops a consensus HCV E1E2 antigen that engages germline B cell precursors of broadly neutralizing antibodies.

The paper evaluates adjuvant effects on immune responses in virosome-based SARS-CoV-2 vaccines, finding distinct impacts on humoral and cellular immunity.

This study shows that fusing C3d to HIV-1 Env immunogens enhances germinal center responses and improves vaccine immunogenicity.

This study generates bispecific antibodies targeting two distinct HCV E1E2 epitopes, showing enhanced neutralization breadth and potency compared to monospecific antibodies.

This study develops bispecific antibodies that target conserved regions on the SARS-CoV-2 spike protein, showing improved neutralization breadth against multiple sarbecovirus strains.

This study shows that chemical cross-linking with EDC stabilizes HIV-1 Env trimers without significant structural distortion, improving their stability, morphology, antigenicity, and immunogenicity for vaccine development.